Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
Lineage Cell Therapeutics said the USPTO has issued U.S. Patent No. 12,692,476 with claims covering its proprietary AlloSCOPE cell manufacturing platform, including the AlloSCOPE 5D technology, with an expected expiration date of June 9, 2043. The 5D method merges 2D-like growth control with 3D bioreactor scale, and management believes it can support commercial-scale production of high-dose cell therapies requiring as many as a billion cells per patient, such as potential islet-cell treatments for Type 1 Diabetes.
Key figures
- Patent number
- 12,692,476
- Patent expiration
- June 9, 2043
- Stated dose requirement
- as high as a billion cells per patient (e.g., Type 1 Diabetes)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.